Human Vascular Endothelial Growth Factor A, Long Form (VEGFA) Protein

Este producto es parte de VEGFA - Vascular Endothelial Growth Factor A
Product Graph
416€ (20 µg)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Human Vascular Endothelial Growth Factor A, Long Form (VEGFA) Protein
category
Proteins and Peptides
provider
Abbexa
reference
abx694218
tested applications
SDS-PAGE

Description

Human Vascular Endothelial Growth Factor A, Long Form (VEGFA) Protein is a recombinant Human protein expressed in HEK293 cells.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Proteins and Peptides
Host
HEK293 cells
Origin
Human
Observed MW
Molecular Weight: Calculated MW: 20.9 kDa  Observed MW (SDS-PAGE): 22 kDa
Sequence Fragment: Met1-Arg191
Tag: C-terminal His tag
Expression
Recombinant
Purity
>95% (SDS-PAGE)
Size 1
20 µg
Size 2
100 µg
Form
Lyophilized Reconstitute in sterile H2O. Do not vortex.
Tested Applications
SDS-PAGE
Buffer
Prior to lyophilization: PBS, pH 7.4, containing 5% - 8% Trehalose, Mannitol and 0.01% Tween-80.
Availability
Shipped within 5-15 working days.
Storage
Store lyophilized between -20 °C and -80 °C.
Dry Ice
No
UniProt ID
P15692
Alias
L-VEGF,MVCD1,VEGF,VPF,Vascular permeability factor
Background
Protein VEGFA
Status
RUO
Note
This product is for research use only.   Not for human consumption, cosmetic, therapeutic or diagnostic use.

Descripción

VEGFA is a key member of the vascular endothelial growth factor (VEGF) family and plays a crucial role in angiogenesis, vascular permeability, and endothelial cell proliferation VEGFA binds primarily to its receptors VEGFR-1 and VEGFR-2, triggering signaling pathways like PI3K/AKT and ERK/MAPK to promote blood vessel formation during embryonic development, wound healing, and tissue repair Dysregulated VEGFA expression is associated with pathological angiogenesis observed in cancer, diabetic retinopathy, and age-related macular degeneration (AMD) VEGFA also increases vascular permeability by altering endothelial junctions, contributing to fluid leakage in conditions such as inflammation and tumors Targeted therapies, such as bevacizumab and other anti-VEGF agents, inhibit VEGFA activity to suppress angiogenesis and tumor growth in various cancers and ocular diseases

Related Products

EG0049

Goat VEGF-A (Vascular Endothelial cell Growth Factor A) ELISA Kit

Ver Producto
EGP0053

Guinea pig VEGF-A (Vascular Endothelial cell Growth Factor A) ELISA Kit

Ver Producto
FNab09391

VEGFA antibody

VEGFA, also named as VEGF or VPF, belongs to the PDGF/VEGF growth factor family. It is a growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. VEGFA induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. It binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. Defects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1(MVCD1). VEGFA has 13 isoforms with MW 16kd to 45kd. Some isoforms has homodimer form, such as VEGFA189(38kd), VEFGA110(34kd). VEGFA is a 34kd to 42kd, dimeric, disulfide-bound glycoprotein. VEGF-A exists in at least seven homodimeric isoforms. The monomers consist of 121, 145, 148, 165, 183, 189, or 206 amino acids(PMID:15602010).

Ver Producto